Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly 2019; 149:w20170.
27.12.2019
Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland
27.12.2019
Swiss Med Wkly 2019; 149:w20170
Bhadhuri Arjun, Insinga Ralph, Guggisberg Patrik, Panje Cédric, Schwenkglenks Matthias
Weiter
